naproxen and tirzepatide FDA Says Compounded Must Exit the Market Naproxen + Tirzepatide: Safety, Interactions

These findings highlight the importance of targeted therapeutic strategies based on HF phenotypes

Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation randomised placebo-controlled trial with safety extension

Sterile needles prevent contamination during vial access procedures

effective/dated: August 25, 2025

In 2025, the court allowed the core failure-to-warn claims to proceed but imposed strict evidentiary requirements, requiring objective diagnostic testing to confirm gastric injury

Introduction: The Compounding Shift in 2025 The story of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an intriguing tale of success, drug shortage and unintentional consequences